Applications published 29 June 2011

Published: 16-Aug-2011
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • Method of treating atrial fibrillation
    Gilead Sciences 2337559*

  • Use of 5-hydroxy-2-hyrdoxymethyl-y-pyrone (HMP) an a leishmanicidal agent
    Universidade Federal Do Pará 2337560*

  • Use of tocotrienol compsn for the prevention of cancer
    Davos Life Science 2337561*

  • Antifungal compounds containing benzothiazolinone, benzoxazinone or benzoxazolinone and process thereof
    Council of Scientific and Industrial Research, New Delhi; Fdc Limited 2337562*

  • Modulators of aldehyde dehydrogenase activity and methods of use thereof
    The Board of Trustees of the Leland Stanford Junior University 2337563*

  • A method for combating adverse effects arising fro antipsychotic treatment
    NeuroSearch 2337564*

  • Stable solid oral co-dosage formulations
    Sequoia Pharmaceuticals 2337565*

  • Combinations for the treatment of migraine
    Novartis 2337566*

  • Methods and means for soft tissue engineering
    Ylikomi, Timo; Sarkanen, Jertta-Riina 2337568*

  • Compsns and methods for characterising and restoring gastrointestinal, skin and nasal microbiota
    New York University 2337569*

  • Compsns and methods for inhibiting entry of a hepatic virus
    The Board of Trustees of the University of Illinois 2337570*

  • Methods for determining the bioactivity of TGF-beta in a compsn
    Mead Johnson Nutrition Company 2337571*

  • Whey and thymus function
    Nestec 2337573*

  • Anti-fungal therapy
    University Court of the University of St Andrews 2337574*

  • Methods of treatment using single doses of oritavancin
    Targanta Therapeutics 2337575*

  • Treatment of mood and anxiety disorders
    Universite Pierre et Marie Curie; Centre National de la Recherche Scientifique 2337576*

  • Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogues as adjunctive treatments with anticancer agents
    The Administrators of the Tulane Educational Fund 2337577*

  • Compsn and methods for modulating toll-like receptor activity
    Opsona Therapeutics 2337578*

  • Cancer treatments with radiation and immunocytokines
    Merck Patent 2337579*

  • New protecting compsns for recombinantly produced factor VIII
    Octapharma 2337580*

  • Synthetic gene construct encoding an HIV-1 gag and the use thereof for obtaining anti-HIV-1 vaccines
    Institut National de la Sante er de la Recherche Medicale 2337581*

  • Combination of HCV NS3 protease inhibitor with interferon and ribavirin
    Boehringer Ingelheim International 2337583*

  • Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
    CV Ingenuity 2337584*

  • Polymer conjugates of GLP-2-like peptides
    Nektar Therapeutics 2337585*

  • Method of production of polyanionic drug-carrier conjugates
    Instytut Immunologii I Terapii Doswiadczalnej Pan 2337586*

  • Imaging agents of fibrotic diseases
    Nitto Denko 2337587*

  • Improved apparatus and method for measuring the concentration of gases in a sterilisation chamber
    Sterilucent 2337588*

  • Method of dispensing a volatile material
    SC Johnson & Son 2337589*

  • Methods of treating a botulinum toxin related condition in a subject
    Absolute Science 2337778*

  • 2-oxo-1,2-dihydro-quinoline modulators of immune function
    Teva Pharmaceutical Industries 2337779*

  • Dithiolane compounds; compsns containing them; uses for photoprotecting the skin
    L’Oréal 2337780*

  • Anti-viral compounds to treat HCV infection
    Abbott Laboratories 2337781*

  • Anti-tumour activity of AECHL-I, a novel triterpenoid isolated from ailanthus excelsa in vitro and in vivo
    Department of Biotechnology, CGO Complex; National Centre for Cell Science, India 2337782*

  • Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors
    F Hoffmann-La Roche 2337783*

  • Macrocyclic compounds as hepatitis-C virus inhibitors
    Bristol-Myers Squibb 2337784*

  • N-phenyl carbazole-based host material for light-emitting diodes
    Solvay 2337785*

  • Complex salts
    BASF 2337786*

  • Clarification process
    Percivia 2337787*

  • Method of making biologically active alpha-beta peptides
    Wisconsin Alumni Research Foundation 2337788*

  • Genus-wide chlamydial peptide vaccine antigens
    Wayne State University 2337789*

  • Clostridial neurotoxins with altered persistency
    Merz Pharma 2337790*

  • Utilisation of fatty acid desaturases from hemiselmis spp
    Monsanto Technology 2337791*

See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now